Objective To observe clinical efficacy of Telmisartan combined with Amiodarone in the treatment of atrial fibrillation complicating acute myocardial infarction (AMI). Methods 130 patients with atrial fibrillation complicating AMI admitted to Zhengzhou Hospital of Traditional Chinese Medicine from January 2008 to March 2011 were selected as subjects and divided into observation group and control group, with 65 cases in each group. Both groups were given Amiodarone infusion and the observation group was given Telmisartan in addition. Clinical efficacies of the two groups were compared. Results Cardioversion rates showed no significant difference between the two groups 24 h and 3 d after treatment (P > 0.05), while those after 5 d and 7 d treatment were significantly different between the two groups (P < 0.05). Hospitalized days of the two groups were not significantly different (P > 0.05), but hospital mortality of observation group was significantly lower than that of control group (P < 0.05). Adverse reactions were mild, liver and kidney function and hemorheology showed no obvious abnormalities after completion of treatment. Conclusion Telmisartan combined with Amiodarone has satisfactory results in the treatment of atrial fibrillation complicating AMI. It can improve short-term cardioversion rate and reduce mortality, with high safety, thus it is worthy of clinical application.%目的 观察替米沙坦联合胺碘酮治疗急性心肌梗死(AMI)合并心房颤动的临床疗效.方法 选取郑州市中医院2008年1月～2011年3月收治的130例AMI合并心房颤动患者作为研究对象,将其分为观察组和对照组,各65例.两组患者均给予胺碘酮静脉滴注,观察组患者加用替米沙坦治疗,比较两组患者的临床疗效.结果 治疗24 h、3 d后两组患者房颤转复率比较差异无统计学意义(P ＞ 0.05),治疗5、7 d后两组患者房颤转复率比较差异有统计学意义(P ＜ 0.05).两组患者住院天数比较差异无统计学意义(P ＞ 0.05),但观察组院内病死率明显低于对照组,差异有统计学意义(P ＜ 0.05).两组不良反应轻微,治疗完成后检查肝肾功能及血液流变学指标,均未见明显异常.结论 替米沙坦联合胺碘酮治疗AMI合并心房颤动效果理想,可提高短期房颤转复率,降低病死率,且安全性较高,值得推广应用.
展开▼
